
Sign up to save your podcasts
Or


With me today is Dr. Mark Pimentel who really needs no introduction to the SIBO community. He's the executive director of the MAST program or Medically Associated Science and Technology. He's professor of medicine at Geffen School of Medicine at Cedar-Sinai Medical Center in L.A. A few of Dr. Pimentel's most significant accomplishments include the discovery of rifaximin as a treatment for IBS. He also developed the first blood test for IBS based on IBS being derived from acute gastroenteritis; the antibody testing. He described the association between IBS and bacterial overgrowth, which forms the basis of microbiome therapies in this condition, as well as uncovering that methanogens are causing constipations in humans.
By Dr Nirala Jacobi4.7
115115 ratings
With me today is Dr. Mark Pimentel who really needs no introduction to the SIBO community. He's the executive director of the MAST program or Medically Associated Science and Technology. He's professor of medicine at Geffen School of Medicine at Cedar-Sinai Medical Center in L.A. A few of Dr. Pimentel's most significant accomplishments include the discovery of rifaximin as a treatment for IBS. He also developed the first blood test for IBS based on IBS being derived from acute gastroenteritis; the antibody testing. He described the association between IBS and bacterial overgrowth, which forms the basis of microbiome therapies in this condition, as well as uncovering that methanogens are causing constipations in humans.

781 Listeners

7,207 Listeners

7,285 Listeners

1,537 Listeners

714 Listeners

780 Listeners

1,720 Listeners

9,251 Listeners

8,597 Listeners

1,814 Listeners

375 Listeners

133 Listeners

1,405 Listeners

822 Listeners

233 Listeners